Characterization of a functional V1B vasopressin receptor in the male rat kidney: evidence for cross talk between V1B and V2 receptor signaling pathways. 2021

Annette Hus-Citharel, and Nadine Bouby, and Maithé Corbani, and Julie Mion, and Christiane Mendre, and Judit Darusi, and Csaba Tomboly, and Miguel Trueba, and Claudine Serradeil-Le Gal, and Catherine Llorens-Cortes, and Gilles Guillon
Collège de France, Neuropeptides Centraux et Régulations Hydrique et Cardiovasculaire, Centre Interdisciplinaire de Recherche en Biologie, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Paris, France.

Although vasopressin V1B receptor (V1BR) mRNA has been detected in the kidney, the precise renal localization as well as pharmacological and physiological properties of this receptor remain unknown. Using the selective V1B agonist d[Leu4, Lys8]VP, either fluorescent or radioactive, we showed that V1BR is mainly present in principal cells of the inner medullary collecting duct (IMCD) in the male rat kidney. Protein and mRNA expression of V1BR were very low compared with the V2 receptor (V2R). On the microdissected IMCD, d[Leu4, Lys8]VP had no effect on cAMP production but induced a dose-dependent and saturable intracellular Ca2+ concentration increase mobilization with an EC50 value in the nanomolar range. This effect involved both intracellular Ca2+ mobilization and extracellular Ca2+ influx. The selective V1B antagonist SSR149415 strongly reduced the ability of vasopressin to increase intracellular Ca2+ concentration but also cAMP, suggesting a cooperation between V1BR and V2R in IMCD cells expressing both receptors. This cooperation arises from a cross talk between second messenger cascade involving PKC rather than receptor heterodimerization, as supported by potentiation of arginine vasopressin-stimulated cAMP production in human embryonic kidney-293 cells coexpressing the two receptor isoforms and negative results obtained by bioluminescence resonance energy transfer experiments. In vivo, only acute administration of high doses of V1B agonist triggered significant diuretic effects, in contrast with injection of selective V2 agonist. This study brings new data on the localization and signaling pathways of V1BR in the kidney, highlights a cross talk between V1BR and V2R in the IMCD, and suggests that V1BR may counterbalance in some pathophysiological conditions the antidiuretic effect triggered by V2R activation.NEW & NOTEWORTHY Although V1BR mRNA has been detected in the kidney, the precise renal localization as well as pharmacological and physiological properties of this receptor remain unknown. Using original pharmaceutical tools, this study brings new data on the localization and signaling pathways of V1BR, highlights a cross talk between V1BR and V2 receptor (V2R) in the inner medullary collecting duct, and suggests that V1BR may counterbalance in some pathophysiological conditions the antidiuretic effect triggered by V2R activation.

UI MeSH Term Description Entries
D008297 Male Males
D009481 Neurophysins Carrier proteins for OXYTOCIN and VASOPRESSIN. They are polypeptides of about 10-kDa, synthesized in the HYPOTHALAMUS. Neurophysin I is associated with oxytocin and neurophysin II is associated with vasopressin in their respective precursors and during transportation down the axons to the neurohypophysis (PITUITARY GLAND, POSTERIOR). Neurophysin,Neurophysin I,Neurophysin II,Neurophysin III,Oxytocin-Associated Neurophysin,Vasopressin-Associated Neurophysin,Neurophysin, Oxytocin-Associated,Neurophysin, Vasopressin-Associated,Oxytocin Associated Neurophysin,Vasopressin Associated Neurophysin
D011498 Protein Precursors Precursors, Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001127 Arginine Vasopressin The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE. Argipressin,Vasopressin, Arginine,Arg-Vasopressin,Argipressin Tannate,Arg Vasopressin
D014667 Vasopressins Antidiuretic hormones released by the NEUROHYPOPHYSIS of all vertebrates (structure varies with species) to regulate water balance and OSMOLARITY. In general, vasopressin is a nonapeptide consisting of a six-amino-acid ring with a cysteine 1 to cysteine 6 disulfide bridge or an octapeptide containing a CYSTINE. All mammals have arginine vasopressin except the pig with a lysine at position 8. Vasopressin, a vasoconstrictor, acts on the KIDNEY COLLECTING DUCTS to increase water reabsorption, increase blood volume and blood pressure. Antidiuretic Hormone,Antidiuretic Hormones,beta-Hypophamine,Pitressin,Vasopressin,Vasopressin (USP),Hormone, Antidiuretic,beta Hypophamine
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D017483 Receptors, Vasopressin Specific molecular sites or proteins on or in cells to which VASOPRESSINS bind or interact in order to modify the function of the cells. Two types of vasopressin receptor exist, the V1 receptor in the vascular smooth muscle and the V2 receptor in the kidneys. The V1 receptor can be subdivided into V1a and V1b (formerly V3) receptors. Antidiuretic Hormone Receptors,Receptors, V1,Receptors, V2,V1 Receptors,V2 Receptors,Vasopressin Receptors,8-Arg-Vasopressin Receptor,Antidiuretic Hormone Receptor,Antidiuretic Hormone Receptor 1a,Antidiuretic Hormone Receptor 1b,Arginine Vasopressin Receptor,Argipressin Receptor,Argipressin Receptors,Receptor, Arginine(8)-Vasopressin,Renal-Type Arginine Vasopressin Receptor,V1 Receptor,V1a Vasopressin Receptor,V1b Vasopressin Receptor,V2 Receptor,Vascular-Hepatic Type Arginine Vasopressin Receptor,Vasopressin Receptor,Vasopressin Receptor 1,Vasopressin Type 1A Receptor,Vasopressin V1a Receptor,Vasopressin V1b Receptor,Vasopressin V2 Receptor,Vasopressin V3 Receptor,8 Arg Vasopressin Receptor,Hormone Receptor, Antidiuretic,Hormone Receptors, Antidiuretic,Receptor, Antidiuretic Hormone,Receptor, Arginine Vasopressin,Receptor, Argipressin,Receptor, V1,Receptor, V2,Receptor, Vasopressin,Receptor, Vasopressin V1b,Receptor, Vasopressin V3,Receptors, Antidiuretic Hormone,Receptors, Argipressin,Renal Type Arginine Vasopressin Receptor,V1b Receptor, Vasopressin,Vascular Hepatic Type Arginine Vasopressin Receptor,Vasopressin Receptor, V1b
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

Annette Hus-Citharel, and Nadine Bouby, and Maithé Corbani, and Julie Mion, and Christiane Mendre, and Judit Darusi, and Csaba Tomboly, and Miguel Trueba, and Claudine Serradeil-Le Gal, and Catherine Llorens-Cortes, and Gilles Guillon
April 1996, The American journal of physiology,
Annette Hus-Citharel, and Nadine Bouby, and Maithé Corbani, and Julie Mion, and Christiane Mendre, and Judit Darusi, and Csaba Tomboly, and Miguel Trueba, and Claudine Serradeil-Le Gal, and Catherine Llorens-Cortes, and Gilles Guillon
March 1998, The Biochemical journal,
Annette Hus-Citharel, and Nadine Bouby, and Maithé Corbani, and Julie Mion, and Christiane Mendre, and Judit Darusi, and Csaba Tomboly, and Miguel Trueba, and Claudine Serradeil-Le Gal, and Catherine Llorens-Cortes, and Gilles Guillon
September 1996, Endocrinology,
Annette Hus-Citharel, and Nadine Bouby, and Maithé Corbani, and Julie Mion, and Christiane Mendre, and Judit Darusi, and Csaba Tomboly, and Miguel Trueba, and Claudine Serradeil-Le Gal, and Catherine Llorens-Cortes, and Gilles Guillon
July 1995, Biochemical and biophysical research communications,
Annette Hus-Citharel, and Nadine Bouby, and Maithé Corbani, and Julie Mion, and Christiane Mendre, and Judit Darusi, and Csaba Tomboly, and Miguel Trueba, and Claudine Serradeil-Le Gal, and Catherine Llorens-Cortes, and Gilles Guillon
December 1994, Biochemical and biophysical research communications,
Annette Hus-Citharel, and Nadine Bouby, and Maithé Corbani, and Julie Mion, and Christiane Mendre, and Judit Darusi, and Csaba Tomboly, and Miguel Trueba, and Claudine Serradeil-Le Gal, and Catherine Llorens-Cortes, and Gilles Guillon
June 2013, British journal of pharmacology,
Annette Hus-Citharel, and Nadine Bouby, and Maithé Corbani, and Julie Mion, and Christiane Mendre, and Judit Darusi, and Csaba Tomboly, and Miguel Trueba, and Claudine Serradeil-Le Gal, and Catherine Llorens-Cortes, and Gilles Guillon
November 1996, Molecular and cellular endocrinology,
Annette Hus-Citharel, and Nadine Bouby, and Maithé Corbani, and Julie Mion, and Christiane Mendre, and Judit Darusi, and Csaba Tomboly, and Miguel Trueba, and Claudine Serradeil-Le Gal, and Catherine Llorens-Cortes, and Gilles Guillon
March 1998, Biology of reproduction,
Annette Hus-Citharel, and Nadine Bouby, and Maithé Corbani, and Julie Mion, and Christiane Mendre, and Judit Darusi, and Csaba Tomboly, and Miguel Trueba, and Claudine Serradeil-Le Gal, and Catherine Llorens-Cortes, and Gilles Guillon
September 1998, The Journal of biological chemistry,
Annette Hus-Citharel, and Nadine Bouby, and Maithé Corbani, and Julie Mion, and Christiane Mendre, and Judit Darusi, and Csaba Tomboly, and Miguel Trueba, and Claudine Serradeil-Le Gal, and Catherine Llorens-Cortes, and Gilles Guillon
May 2000, Journal of neuroendocrinology,
Copied contents to your clipboard!